Nuplazid Complete Response Letter For Dementia Psychosis Driven By Effectiveness Concerns In Subgroups

 
• By Jessica Merrill

Acadia says the US FDA’s view has shifted from what was previously agreed upon for approval of an sNDA for pimavanserin in a broad dementia-related psychosis indication.

stop sign
Acadia's Nuplazid expansion plans were halted by FDA • Source: Alamy (LAMB / Alamy Stock Photo/Alamy Stock Photo)

More from Product Reviews

More from Pink Sheet